» rgunnam Submit Press Releases

GlobalData valued the global (to include the US, the UK, France, Germany, Italy, Spain and Japan) Sickle Cell Anemia therapeutics market at $33m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 18.9% to reach $130m in 2018. There are no approved branded drugs in the

In last decade, China has established itself as the largest petrochemicals market, owing to impressive demand from its large population creating an astonishing growth in demand for petrochemicals in China. It is now world’s largest petrochemicals consumer, surpassing the US. Government focus on

GlobalData’s analysis estimated the allergic rhinitis therapeutics market (the US, the UK, France, Germany, Italy, Spain and Japan) to be worth $4,406.6m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 1.3% for the next eight years to reach $3,981.0m by 2018. The

GlobalData has estimated that the global ACS therapeutics market valued $6,055.3m in 2005, before increasing at a compounded annual growth rate (CAGR) of 5.8% to reach $8,038.5m in 2010. The market is expected to increase to $8,509.2m by 2018, at a slow CAGR of 0.7%. The slow growth in the

GlobalData’s analysis shows that the global osteoporosis therapeutics market stood at $6.9 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $8.5 billion in 2010. GlobalData forecasts that the global osteoporosis therapeutics market will grow moderately at a CAGR

GlobalData has estimated that the global Crohn’s Disease (CD) therapeutics market was worth $3.6 billion in 2010, which grew at a compound annual growth rate (CAGR) of 25.2% from $1.2 billion in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the launch of

GlobalData valued the global Lennox-Gastaut Syndrome (LGS) therapeutics market at $86.44m in 2010, and it is forecast to grow at a compound annual growth rate (CAGR) of 13.45% during 2010-2018 to reach $237.21m by 2018. The patents for LGS of leading second generation antiepileptic drugs (AEDs)

GlobalData estimates that the global celiac disease therapeutics market will worth $512.3m in 2017. This market is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.9% to reach $664.4m by 2019. This high growth forecast is primarily attributed to the increased uptake of the pipeline

The orphan autoimmune disorder therapeutics market is one of the steadily growing markets in autoimmune therapeutics and is expected to show a significant growth in forecast period. The ITP and ALS market are the leading contributors to the global orphan autoimmune disorder therapeutics market in

The effectiveness of new drugs against disorders affecting the central nervous system is greatly dependent on the use of rating scales in randomized clinical trials. Some of the ratings scales used in clinical trials for drugs targeting CNS disorders include the Brief Psychiatric Rating Scale

The global Tuberculosis (TB) infection market was worth $38.3m in 2010. It is expected to decline at a Compound Annual Growth Rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the

The global insulin pumps market was valued at $725.9m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.8% to reach $1.2 billion in 2017. The market is expected to be driven by a rapid increase in the prevalence of diabetes, availability of reimbursement, positive

The global Computed Tomography (CT) systems market was estimated to be worth $3.4 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5% to reach $4.8 billion by 2017. The future growth of the market is expected to be driven by high slice CT systems and low-dose CT

The global Chemotherapy-induced Neutropenia (CIN) therapeutics market was worth $3.6 billion in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018.

GlobalData estimates that the global brain hemorrhage therapeutics market was worth $358m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 3% to $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to its stable prevalence, a high mortality

GlobalData estimates that the global insomnia therapeutics market was worth $918m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $1,343m by 2018. This steady growth is primarily attributed to the expected launch of pipeline products in 2014 (such as Intermezzo,

GBI Research has found that the global ophthalmology market will grow at a moderate rate due to the impact of generic erosion in markets such as glaucoma and allergic conjunctivitis. However, unmet need in the wet age macular degeneration and diabetic retinopathy markets make the ophthalmology

The global hormonal contraceptive market is a fast growing market, with oral contraceptives considered to be the most common method of avoiding unplanned pregnancies. In 2010, the global contraceptives market was valued at $15.5 billion and is forecast to grow to $19.2 billion by 2017, which

GBI Research found that the global metabolic disorders therapeutics market is attractive despite product failures. The major factor driving the growth of the market is the rising incidence of obesity and the diabetes diseased population in key markets such as the US, the UK and Germany. The

The endoscopy devices market in the emerging economies of China, India and Brazil grew at a Compounded Annual Growth Rate (CAGR) of 4%, 3% and 3%. The endoscopy devices market in China is forecast to reach $107m in 2017. The main driver for the Chinese market is the continuing investment by the

GlobalData estimates that the global type 1 diabetes therapeutics market was worth $2,331m in 2010 after increasing at a Compound Annual Growth Rate (CAGR) of 17.4% during the period 2005-2010. During 2010-2018 the market is expected to record a CAGR of 8.7%, to reach $4,552.4m by 2018. The

GlobalData estimates that the global psoriasis therapeutics market was worth $3.6 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 8.1% to reach $6.7 billion by 2018. This high growth forecast is primarily attributed to the currently approved drugs reaching

The Autism Spectrum Disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.5% over the next eight years to reach $5.5 billion by 2018. This market growth is primarily attributed to the high prevalence (0.6 to 1%)

Since its first drilling activity in 2008, Eagle Ford shale has witnessed rapid developments. Since 2010, mergers, acquisitions and asset transaction deals worth about $15 billion were signed in the Eagle Ford shale plays. This trend is expected to continue in the near-term as some major oil and

In 2010, the global pain management market was worth approximately $28.6 billion, representing a compound annual growth rate (CAGR) of 5.3% between 2002 and 2010. By 2017, the global pain management market is estimated to reach $35.1 billion, indicating a CAGR of 3.0% between 2010 and 2017. The

The global demand for styrene has been steadily increasing over the last ten years. In 2000, global styrene demand stood at 17,298,363 tons, before increasing to 21,657,608 tons in 2010. A significant portion of the increase in demand for styrene was from the Asia-Pacific region, and the same

The global fabric filter market is expected to see significant growth over the forecast period, growing from $625m in 2010 to $1,211m in 2015. The major driver for the fabric filter market during this period is expected to be the stringent regulations controlling power plant Particulate Matter

The global nuclear imaging equipment market was estimated to be worth $1.8 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7% to reach $2.9 billion by 2017. The market is expected to be driven by increasing applications of these systems in diagnosing oncological

The global market for Medical Resonance Imaging (MRI) systems was valued at $3.8 billion and is forecast to reach $5.6 billion at a Compound Annual Growth Rate (CAGR) of 6%. Future growth is attributed to technological advances improving patient comfort, such as open MRI systems and short bore

The global X-Ray systems market is expected to grow at a CAGR of 4% from 2010 to reach $4.8 billion in 2017. The growth will be driven by a higher demand for X-Ray imaging due to the elderly population, an increase in public-private partnerships and investment in healthcare infrastructure in

The global market for external defibrillators, which was valued at $1.5 billion in 2010, is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% over the period 2010 – 2017 to exceed $2.2 billion by 2017. The market for manual defibrillators used in hospital setups will grow at a

The global peripheral vascular stents (PVS) market is expected to grow at a compounded annual growth rate (CAGR) of 4% from 2010, to reach $1.3 billion by 2017. Minimally invasive procedures such as peripheral angioplasty have emerged as the preferred choice in the treatment of peripheral

The global Renal Dialysis Services (RDS) market, valued at approximately $57 billion in 2010, is expected to grow at a modest Compounded Annual Growth Rate (CAGR) of 4% to reach about $75 billion by 2017. While Hemodialysis (HD) service revenues are expected to grow on par with the overall

GlobalData estimates that the global polycystic ovarian syndrome (PCOS) therapeutics market was valued at $656m in 2010. It is expected to grow at a static compound annual growth rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly

GlobalData estimated the global periodontal disease therapeutics market to be valued at $1,607m in 2010. It is expected to grow at a compound annual growth rate (CAGR) of approximately 6.4% and reach $2,638m in 2018. The treatment of periodontal disease is dominated by dental procedures and

The global wind energy market witnessed huge growth from 2009 to 2010 as total wind power capacity grew by 22.3%. Global wind energy installed capacity increased at a compound annual growth rate (CAGR) of 27.9% from 74,107 megawatt (MW) in 2006 to 198,203 MW in 2010, of which 36,100 MW came

The cardiovascular devices market in emerging countries, which includes China, Brazil and India, was worth $2.1 billion in 2010 and is expected to reach $2.8 billion in 2017, growing at a Compound Annual Growth Rate (CAGR) of 4%. The cardiovascular devices market in these countries is expected to

The global spinal non-fusion devices market was valued at $569.6m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to reach $950.1m by 2017. The market is expected to be driven by the increasing incidence of spinal disorders and the rising medical tourism trend, as

The Global Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy Defibrillators (CRT-D) Market is Forecast to Grow at a Rate of 5% Over the Period 2010–2017 The global ICD and CRT-D market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5% over the

GlobalData estimates that the global Peripheral Artery Disease (PAD) therapeutics market was valued at $6,458.9m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.8% over the next eight years to reach $7,422.3m by 2018. The current PAD therapeutics market is flooded

The global heart failure (HF) therapeutics market, valued at $3,269m in 2005, has grown at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.9% over the next eight years, to

GlobalData estimated the global Urinary Incontinence (UI) therapeutics market to be worth $2.6 billion in 2010. It is expected to grow to $4.5 billion, with a Compound Annual Growth Rate (CAGR) of 7.0% by 2018. The modest growth is primarily attributable to the patent expiries of key drugs in the

GlobalData estimates that the global bipolar disorder therapeutics market was valued at $6,242m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.0% over the next eight years, to reach $7,340m by 2018. Atypical antipsychotics, mood stabilizers, and antidepressants are

The dental devices market is expected to grow at a compound annual growth rate (CAGR) of 7% and reach $13.3 billion in 2017, from $8.4 billion in 2010. Technological advances, an increase in the percentage of elderly population, a rise in healthcare expenditure in emerging markets and increased

GBI Research compared the number of clinical trials conducted in orphan diseases in CNS along with the most common CNS disorders. The number of clinical trials in orphan disease between 2000 and 2010 accounts for lesser number of clinical trials than other diseases such as Alzheimer’s disease,

Healthcare across the European Union (EU) and majority of the European nations is largely publicly financed and is provided by health insurance systems; hence, the governments of European nations play a key role in providing healthcare for their citizens. Health is a high priority for Europe’s

Wind is one of the fastest growing energy sources in the world. From an emerging fuel source 20 years ago, wind energy has grown to become a commercial electricity generating technology in over 87 countries. Developments in technology have paved the way for more effective and reliable equipment

The global cancer vaccines market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 21% between 2010 and 2017, reaching revenues of $6.3 billion in 2017 from $1.7 billion in 2010. The cancer vaccines market was occupied by three vaccines, namely, Gardasil from Merck, Cervarix from

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications. From 2002, the market grew at a rate of 7.6% to $57.8 billion in 2010, and is forecast to grow at a rate of 5.8% during the forecast period, to produce revenues of $85.9 billion in

The API market revenues in the Americas are expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2010 to 2015. As the North American pharmaceutical market recovers from the impacts of economic downturn, API market revenues are expected to witness steady growth.The faster growing